NASDAQ:VERU - Veru Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$2.29 +0.04 (+1.78 %)
(As of 06/17/2018 04:00 PM ET)
Previous Close$2.29
Today's Range$2.24 - $2.3438
52-Week Range$0.90 - $3.00
Volume93,990 shs
Average Volume124,119 shs
Market Capitalization$122.54 million
P/E RatioN/A
Dividend YieldN/A
Beta0.62

About Veru (NASDAQ:VERU)

Veru logoVeru Inc. operates as a urology and oncology biopharmaceutical company. The company operates through two segments, Commercial; and Research and Development. It offers FC2 Female Condom for unintended pregnancy and sexually transmitted infections, including HIV/AIDS and the Zika virus; and PREBOOST benzocaine medicated individual wipes for the prevention of premature ejaculation. The company's urology drug candidates include Tamsulosin delayed release sachet and Tamsulosin XR capsules that are under bioequivalence study for the treatment of benign prostatic hyperplasia; and Solifenacin delayed release granules, which are under bioequivalence study for the treatment of overactive bladder. Its urology drug candidates also comprise Tadalafil-Finasteride combination capsules that are under bioequivalence study for the treatment of men with lower urinary tract symptoms and enlarged prostate; VERU-944, which is in Phase II clinical trial for the treatment of hot flashes in men on prostate cancer hormonal therapies; and VERU-722 that is in Phase II clinical trial for the treatment of male infertility caused by testicular dysfunction. The company's oncology drug candidate is VERU-111, a novel oral alpha and beta tubulin inhibitor, which is under preclinical study for the treatment of metastatic prostate, breast, endometrial, ovarian, and other cancers. It also develops VERU-111/VERU-112, a novel oral agent targeting colchicine binding site that is under preclinical study for the treatment of gout and familial mediterranean fever. Veru Inc. serves agencies, non-government organizations, ministries of health, and other governmental agencies through distributors and retailers primarily in the United States, Brazil, Spain, France, and the United Kingdom. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was founded in 1896 and is headquartered in Miami, Florida.

Receive VERU News and Ratings via Email

Sign-up to receive the latest news and ratings for VERU and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Fabricated rubber products, not elsewhere classified
Sub-IndustryPersonal Products
SectorMedical
SymbolNASDAQ:VERU
CUSIP31446210
Phone305-509-6897

Debt

Debt-to-Equity Ratio0.14
Current Ratio1.53
Quick Ratio1.19

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$13.66 million
Price / Sales8.97
Cash FlowN/A
Price / CashN/A
Book Value$0.91 per share
Price / Book2.52

Profitability

EPS (Most Recent Fiscal Year)($0.25)
Net Income$-6,610,000.00
Net Margins-87.78%
Return on Equity-21.72%
Return on Assets-16.38%

Miscellaneous

Employees175
Outstanding Shares53,510,000

Veru (NASDAQ:VERU) Frequently Asked Questions

What is Veru's stock symbol?

Veru trades on the NASDAQ under the ticker symbol "VERU."

How were Veru's earnings last quarter?

Veru Inc (NASDAQ:VERU) announced its quarterly earnings data on Wednesday, May, 9th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.05) by $0.02. The company had revenue of $2.57 million for the quarter, compared to analysts' expectations of $7.60 million. Veru had a negative net margin of 87.78% and a negative return on equity of 21.72%. View Veru's Earnings History.

When is Veru's next earnings date?

Veru is scheduled to release their next quarterly earnings announcement on Tuesday, August, 14th 2018. View Earnings Estimates for Veru.

What price target have analysts set for VERU?

2 equities research analysts have issued twelve-month target prices for Veru's shares. Their forecasts range from $5.00 to $5.00. On average, they expect Veru's share price to reach $5.00 in the next year. View Analyst Ratings for Veru.

Who are some of Veru's key competitors?

Who are Veru's key executives?

Veru's management team includes the folowing people:
  • Mr. O. B. Parrish, Co-Founder & Vice Chairman (Age 85)
  • Ms. Michele Greco, CFO, Exec. VP of Fin. & Chief Admin. Officer (Age 59)
  • Dr. Harry Fisch, Chief Corp. Officer & Director (Age 59)
  • Dr. Mitchell S. Steiner, Pres, CEO & Director (Age 57)
  • Mr. Kevin J. Gilbert, Sr. VP of Corp. Devel. & Legal and Sec.

Has Veru been receiving favorable news coverage?

Headlines about VERU stock have been trending somewhat positive this week, according to Accern. Accern identifies positive and negative news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Veru earned a daily sentiment score of 0.11 on Accern's scale. They also assigned news coverage about the company an impact score of 46.61 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.

How do I buy shares of Veru?

Shares of VERU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Veru's stock price today?

One share of VERU stock can currently be purchased for approximately $2.29.

How big of a company is Veru?

Veru has a market capitalization of $122.54 million and generates $13.66 million in revenue each year. The company earns $-6,610,000.00 in net income (profit) each year or ($0.25) on an earnings per share basis. Veru employs 175 workers across the globe.

How can I contact Veru?

Veru's mailing address is 4400 Biscayne Boulevard Suite 888, Miami FL, 33137. The company can be reached via phone at 305-509-6897 or via email at [email protected]


MarketBeat Community Rating for Veru (VERU)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  110 (Vote Outperform)
Underperform Votes:  62 (Vote Underperform)
Total Votes:  172
MarketBeat's community ratings are surveys of what our community members think about Veru and other stocks. Vote "Outperform" if you believe VERU will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VERU will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Veru (NASDAQ:VERU) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
2 Wall Street analysts have issued ratings and price targets for Veru in the last 12 months. Their average twelve-month price target is $5.00, suggesting that the stock has a possible upside of 118.34%. The high price target for VERU is $5.00 and the low price target for VERU is $5.00. There are currently 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $5.00$5.00$5.00$5.00
Price Target Upside: 118.34% upside182.49% upside249.65% upside254.61% upside

Veru (NASDAQ:VERU) Consensus Price Target History

Price Target History for Veru (NASDAQ:VERU)

Veru (NASDAQ:VERU) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/18/2018HC WainwrightSet Price TargetBuy$5.00LowView Rating Details
7/26/2017Rodman & RenshawInitiated CoverageBuy ➝ Buy$5.00HighView Rating Details
(Data available from 6/17/2016 forward)

Earnings

Veru (NASDAQ:VERU) Earnings History and Estimates Chart

Earnings by Quarter for Veru (NASDAQ:VERU)

Veru (NASDAQ:VERU) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.18 EPS
Next Year EPS Consensus Estimate: $-0.2 EPS

Veru (NASDAQ VERU) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/14/2018        
5/9/2018Q2($0.05)($0.07)$7.60 million$2.57 millionViewListenView Earnings Details
2/14/2018Q1 2018($0.03)($0.03)$5.30 million$2.59 millionViewListenView Earnings Details
1/2/2018Q4 2017($0.04)($0.10)$3.69 millionViewN/AView Earnings Details
8/8/2017Q3 2017($0.08)($0.03)$2.20 million$4.31 millionViewN/AView Earnings Details
5/9/2017Q2 2017($0.06)$2.41 millionViewListenView Earnings Details
2/9/2017Q1 2017($0.04)$3.24 millionViewN/AView Earnings Details
12/12/2016Q4 2016($0.06)$3.56 millionViewN/AView Earnings Details
7/28/2016Q3$0.02$5.56 millionViewListenView Earnings Details
2/2/2016Q1$0.05$6.66 million$8.23 millionViewN/AView Earnings Details
12/1/2015Q4$0.02$7.16 millionViewN/AView Earnings Details
7/30/2015Q315$0.04$7.28 million$7.81 millionViewListenView Earnings Details
4/30/2015Q215$0.07$0.06$9.48 million$11.00 millionViewN/AView Earnings Details
2/3/2015Q115$0.07$0.03$9.91 million$6.66 millionViewN/AView Earnings Details
12/2/2014Q314$0.02($0.02)$5.55 millionViewN/AView Earnings Details
7/31/2014Q214$0.05$0.04$7.28 million$7.90 millionViewN/AView Earnings Details
5/1/2014Q2 2014$0.02$0.01$4.35 millionViewN/AView Earnings Details
2/3/2014Q114$0.05$0.05$9.91 million$6.69 millionViewN/AView Earnings Details
12/3/2013Q4$0.14$0.23$9.90 million$4.80 millionViewListenView Earnings Details
8/1/2013Q3 2013$0.08$0.03$7.28 millionViewN/AView Earnings Details
5/2/2013Q2 2013$0.12$7.80 million$9.50 millionViewN/AView Earnings Details
1/30/2013Q1 2013$0.12$8.60 million$9.90 millionViewN/AView Earnings Details
12/4/2012Q4 2012$0.11$0.11ViewN/AView Earnings Details
7/31/2012Q3 2012$0.04$0.09ViewN/AView Earnings Details
5/1/2012Q2 2012$0.01$0.07ViewN/AView Earnings Details
1/31/2012Q1 2012$0.01$0.09ViewN/AView Earnings Details
12/2/2011Q4 2011$0.11$0.07ViewN/AView Earnings Details
8/5/2011Q3 2011$0.06$0.01ViewN/AView Earnings Details
2/4/2011Q1 2011$0.01ViewN/AView Earnings Details
12/3/2010Q4 2010$0.03$0.19ViewN/AView Earnings Details
5/7/2010Q2 2010$0.07ViewN/AView Earnings Details
2/8/2010Q1 2010$0.02ViewN/AView Earnings Details
11/30/2009Q4 2009$0.12ViewN/AView Earnings Details
8/7/2009Q3 2009$0.02ViewN/AView Earnings Details
5/8/2009Q2 2009$0.07ViewN/AView Earnings Details
2/10/2009Q1 2009$0.06ViewN/AView Earnings Details
12/1/2008Q4 2008$0.08ViewN/AView Earnings Details
8/12/2008Q3 2008$0.02ViewN/AView Earnings Details
5/14/2008Q2 2008$0.03ViewN/AView Earnings Details
2/13/2008Q1 2008$0.03ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Veru (NASDAQ:VERU) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
3/25/2014quarterly$0.073.84%4/28/20144/30/20145/7/2014
3/24/2014quarterly$0.074/30/20144/7/2014
12/16/2013quarterly$0.073.56%1/27/20141/29/20142/5/2014
10/4/2013quarterly$0.072.87%10/28/201310/30/201311/6/2013
7/16/2013quarterly$0.072.99%7/29/20137/31/20138/7/2013
3/27/2013quarterly$0.073.87%4/29/20135/1/20135/8/2013
1/3/2013quarterly$0.063.25%1/28/20131/30/20132/6/2013
(Data available from 1/1/2013 forward)

Insider Trades

Veru (NASDAQ VERU) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 37.00%
Institutional Ownership Percentage: 4.80%
Insider Trading History for Veru (NASDAQ:VERU)

Veru (NASDAQ VERU) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/16/2018Harry FischDirectorBuy5,000$1.96$9,800.00View SEC Filing  
3/16/2018Mitchell Shuster SteinerInsiderBuy20,000$1.96$39,200.00View SEC Filing  
3/14/2018Harry FischDirectorBuy10,000$1.87$18,700.00View SEC Filing  
3/12/2018Harry FischDirectorBuy10,000$1.80$18,000.00View SEC Filing  
3/9/2018Harry FischDirectorBuy10,000$1.88$18,800.00View SEC Filing  
3/8/2018Mitchell Shuster SteinerInsiderBuy20,000$1.88$37,600.00View SEC Filing  
3/7/2018Harry FischDirectorBuy24,000$1.62$38,880.00View SEC Filing  
3/6/2018Mitchell Shuster SteinerInsiderBuy20,000$1.50$30,000.00View SEC Filing  
9/15/2017Mitchell Shuster SteinerInsiderBuy100,000$1.63$163,000.007,764,767View SEC Filing  
9/13/2017Harry FischDirectorBuy34,250$1.51$51,717.50View SEC Filing  
8/30/2017Mitchell Shuster SteinerInsiderBuy5,625$1.66$9,337.50View SEC Filing  
8/23/2017Jesus SocorroDirectorBuy7,100$1.44$10,224.007,100View SEC Filing  
6/12/2017Mitchell Shuster SteinerInsiderBuy55,000$1.27$69,850.00645,502View SEC Filing  
6/9/2017Elgar PeerschkeDirectorBuy50,000$1.25$62,500.00145,520View SEC Filing  
6/8/2017Elgar PeerschkeDirectorBuy4,967$1.15$5,712.0593,605View SEC Filing  
6/7/2017Daniel HainesCFOBuy6,000$1.14$6,840.0083,931View SEC Filing  
6/6/2017Elgar PeerschkeDirectorBuy2,852$1.15$3,279.8090,553View SEC Filing  
6/1/2017Daniel HainesCFOBuy10,000$1.10$11,000.0077,931View SEC Filing  
5/30/2017Harry FischDirectorBuy12,000$1.27$15,240.00View SEC Filing  
5/24/2017Harry FischDirectorBuy10,000$1.10$11,000.00View SEC Filing  
5/22/2017Harry FischDirectorBuy24,750$1.02$25,245.00View SEC Filing  
5/17/2017Daniel HainesCFOBuy5,000$1.01$5,050.0067,931View SEC Filing  
5/15/2017Daniel HainesCFOBuy5,000$1.03$5,150.0062,931View SEC Filing  
5/15/2017O B ParrishDirectorBuy20,000$1.02$20,400.00834,849View SEC Filing  
5/12/2017David R BethuneDirectorBuy20,000$1.03$20,600.00415,982View SEC Filing  
5/11/2017Lucy LuDirectorBuy5,000$1.00$5,000.005,000View SEC Filing  
3/20/2017Georges MakhoulDirectorBuy100,000$1.05$105,000.00189,444View SEC Filing  
2/24/2017Daniel HainesCFOBuy7,931$1.03$8,168.9354,000View SEC Filing  
12/15/2016David R BethuneDirectorBuy200$1.06$212.00405,982View SEC Filing  
8/16/2016Andrew S Love JrDirectorBuy20,214$1.39$28,097.46114,626View SEC Filing  
8/15/2016Andrew S Love JrDirectorBuy4,786$1.32$6,317.5293,712View SEC Filing  
6/10/2016Andrew S Love JrDirectorBuy15,000$1.36$20,400.0081,136View SEC Filing  
6/6/2016Andrew S Love JrDirectorBuy1,210$1.40$1,694.0066,136View SEC Filing  
5/24/2016Michele GrecoCFOBuy4,000$1.28$5,120.0067,845View SEC Filing  
5/24/2016O B ParrishCEOBuy10,000$1.29$12,900.00814,849View SEC Filing  
5/23/2016William R Gargiulo JrDirectorBuy500$1.26$630.00102,500View SEC Filing  
5/20/2016David R BethuneDirectorBuy100$1.26$126.00249,115View SEC Filing  
12/18/2015O B ParrishCEOBuy10,000$1.48$14,800.00846,849View SEC Filing  
12/15/2015Andrew S. Love, Jr.DirectorBuy25,000$1.47$36,750.0039,926View SEC Filing  
2/5/2015Karen Louise KingCEOBuy1,000$3.86$3,860.00View SEC Filing  
8/12/2014O B ParrishDirectorBuy5,000$4.05$20,250.00View SEC Filing  
8/6/2014Donna FelchDirectorBuy2,500$3.90$9,750.00View SEC Filing  
8/4/2014Karen Louise KingCEOBuy2,000$3.94$7,880.00View SEC Filing  
5/13/2014Stephen M DearholtDirectorSell203,936$6.05$1,233,812.80View SEC Filing  
3/18/2014William R Gargiulo JrDirectorBuy1,000$6.81$6,810.00View SEC Filing  
3/17/2014O B ParrishDirectorBuy5,000$6.74$33,700.00View SEC Filing  
12/20/2013Stephen M DearholtDirectorBuy2,000$8.27$16,540.00View SEC Filing  
12/18/2013David R BethuneDirectorBuy4,000$8.07$32,280.00View SEC Filing  
3/8/2013Michele GrecoCFOBuy1,000$7.01$7,010.00View SEC Filing  
9/17/2012Stephen M DearholtDirectorSell25,000$7.02$175,500.00View SEC Filing  
8/9/2012Michael PopeVPSell17,056$5.90$100,630.40View SEC Filing  
8/8/2012Richard E WenningerDirectorSell3,260$6.00$19,560.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Veru (NASDAQ VERU) News Headlines

Source:
DateHeadline
Veru to Present at Jefferies 2018 Global Healthcare Conference on Wednesday, June 6thVeru to Present at Jefferies 2018 Global Healthcare Conference on Wednesday, June 6th
finance.yahoo.com - May 30 at 5:34 PM
Opinion: Finally, a simple solution to confusing health-care pricesOpinion: Finally, a simple solution to confusing health-care prices
www.marketwatch.com - May 23 at 8:01 AM
Banned pregnancy drug tied to ADHD generations laterBanned pregnancy drug tied to ADHD generations later
www.reuters.com - May 23 at 8:01 AM
A Guide to Gynecological Exams: What Should — and Shouldnt — HappenA Guide to Gynecological Exams: What Should — and Shouldn't — Happen
www.nytimes.com - May 20 at 5:42 PM
Denise Morrison Quits as Campbell Chief, Further Cutting Female CEO RanksDenise Morrison Quits as Campbell Chief, Further Cutting Female CEO Ranks
www.nytimes.com - May 20 at 5:42 PM
USC tried to protect its reputation more than its female students. Howd that work out?USC tried to protect its reputation more than its female students. How'd that work out?
www.latimes.com - May 20 at 5:42 PM
Female Health (VERU) PT Set at $5.00 by HC WainwrightFemale Health (VERU) PT Set at $5.00 by HC Wainwright
www.americanbankingnews.com - May 18 at 3:53 PM
Veru Announces Publication of Data from Three Cancer Studies as Part of the Upcoming American Society of Clinical Oncology Annual MeetingVeru Announces Publication of Data from Three Cancer Studies as Part of the Upcoming American Society of Clinical Oncology Annual Meeting
finance.yahoo.com - May 17 at 5:30 PM
Veru Announces Publication of Data on Oral VERU-111 in Prostate Cancer in Connection with the 2018 American Society of Clinical Oncology Annual MeetingVeru Announces Publication of Data on Oral VERU-111 in Prostate Cancer in Connection with the 2018 American Society of Clinical Oncology Annual Meeting
finance.yahoo.com - May 17 at 8:25 AM
Female Health (VERU) Cut to Sell at Zacks Investment ResearchFemale Health (VERU) Cut to Sell at Zacks Investment Research
www.americanbankingnews.com - May 16 at 3:55 PM
Mothers Day Gifts For Active WomenMother's Day Gifts For Active Women
www.forbes.com - May 11 at 9:05 AM
Female Health (VERU) Given a $5.00 Price Target at HC WainwrightFemale Health (VERU) Given a $5.00 Price Target at HC Wainwright
www.americanbankingnews.com - May 10 at 7:51 PM
Female Health (VERU) Releases  Earnings Results, Misses Estimates By $0.02 EPSFemale Health (VERU) Releases Earnings Results, Misses Estimates By $0.02 EPS
www.americanbankingnews.com - May 10 at 6:33 PM
Verus (VERU) CEO Mitchell Steiner on Q2 2018 Results - Earnings Call TranscriptVeru's (VERU) CEO Mitchell Steiner on Q2 2018 Results - Earnings Call Transcript
seekingalpha.com - May 9 at 5:34 PM
Veru Reports Fiscal 2018 Second-Quarter Financial ResultsVeru Reports Fiscal 2018 Second-Quarter Financial Results
finance.yahoo.com - May 9 at 8:23 AM
Female Health (VERU) Scheduled to Post Quarterly Earnings on WednesdayFemale Health (VERU) Scheduled to Post Quarterly Earnings on Wednesday
www.americanbankingnews.com - May 7 at 9:16 AM
When Doctors Downplay Womens Health ConcernsWhen Doctors Downplay Women's Health Concerns
www.nytimes.com - May 5 at 8:23 AM
Head to Head Comparison: West Pharmaceutical Services (WST) & Female Health (VERU)Head to Head Comparison: West Pharmaceutical Services (WST) & Female Health (VERU)
www.americanbankingnews.com - May 5 at 1:20 AM
Veru Announces Presentation of Data Demonstrating Efficacy of VERU-111 in a Taxane Resistant Human Prostate Cancer Model at the 2018 American Urological Association MeetingVeru Announces Presentation of Data Demonstrating Efficacy of VERU-111 in a Taxane Resistant Human Prostate Cancer Model at the 2018 American Urological Association Meeting
finance.yahoo.com - May 3 at 5:31 PM
Veru to Report Fiscal 2018 Second-Quarter Financial Results, Host Conference Call on May 9thVeru to Report Fiscal 2018 Second-Quarter Financial Results, Host Conference Call on May 9th
finance.yahoo.com - May 3 at 5:31 PM
Financial Survey: Female Health (VERU) vs. West Pharmaceutical Services (WST)Financial Survey: Female Health (VERU) vs. West Pharmaceutical Services (WST)
www.americanbankingnews.com - May 2 at 11:21 PM
The Best Bespoke Mothers Day Gifts From Female-Owned BrandsThe Best Bespoke Mother's Day Gifts From Female-Owned Brands
www.forbes.com - April 30 at 5:31 PM
Women need to take an active role in their financial livesWomen need to take an active role in their financial lives
www.cnbc.com - April 30 at 9:33 AM
Reviewing Female Health (VERU) and West Pharmaceutical Services (WST)Reviewing Female Health (VERU) and West Pharmaceutical Services (WST)
www.americanbankingnews.com - April 29 at 5:30 AM
Tracks New Gender Rules Could Exclude Some Female AthletesTrack's New Gender Rules Could Exclude Some Female Athletes
www.nytimes.com - April 26 at 5:27 PM
Why the romaine lettuce E. coli outbreak affects more women than menWhy the romaine lettuce E. coli outbreak affects more women than men
abcnews.go.com - April 26 at 5:27 PM
Head to Head Contrast: West Pharmaceutical Services (WST) and Female Health (VERU)Head to Head Contrast: West Pharmaceutical Services (WST) and Female Health (VERU)
www.americanbankingnews.com - April 26 at 3:14 PM
The Menopause-Alzheimers ConnectionThe Menopause-Alzheimer's Connection
www.nytimes.com - April 20 at 5:36 PM
Gender equality in the sciences is improving, but more work is neededGender equality in the sciences is improving, but more work is needed
abcnews.go.com - April 20 at 5:36 PM
Female Health (VERU) Upgraded to Hold by Zacks Investment ResearchFemale Health (VERU) Upgraded to Hold by Zacks Investment Research
www.americanbankingnews.com - April 20 at 11:52 AM
Head-To-Head Analysis: Female Health (VERU) and OMNOVA Solutions (OMN)Head-To-Head Analysis: Female Health (VERU) and OMNOVA Solutions (OMN)
www.americanbankingnews.com - April 18 at 9:17 PM
NYC Removes Statue Honoring 19th Century Surgeon Who Experimented On Female SlavesNYC Removes Statue Honoring 19th Century Surgeon Who Experimented On Female Slaves
www.huffingtonpost.com - April 18 at 8:37 AM
Female Health (VERU) Earns Buy Rating from Analysts at Rodman & RenshawFemale Health (VERU) Earns Buy Rating from Analysts at Rodman & Renshaw
www.americanbankingnews.com - April 15 at 10:00 PM
Female Health (VERU) Stock Rating Upgraded by ValuEngineFemale Health (VERU) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - April 9 at 5:52 PM
Comparing Female Health (VERU) and OMNOVA Solutions (OMN)Comparing Female Health (VERU) and OMNOVA Solutions (OMN)
www.americanbankingnews.com - April 9 at 9:19 AM
OMNOVA Solutions (OMN) vs. Veru (VERU) Head to Head ContrastOMNOVA Solutions (OMN) vs. Veru (VERU) Head to Head Contrast
www.americanbankingnews.com - April 5 at 3:08 AM
Veru (VERU) Downgraded by ValuEngineVeru (VERU) Downgraded by ValuEngine
www.americanbankingnews.com - April 3 at 10:58 PM
Carlisle Companies (CSL) versus Veru (VERU) Head-To-Head SurveyCarlisle Companies (CSL) versus Veru (VERU) Head-To-Head Survey
www.americanbankingnews.com - April 1 at 5:15 PM
Veru (VERU) PT Set at $5.00 by HC WainwrightVeru (VERU) PT Set at $5.00 by HC Wainwright
www.americanbankingnews.com - March 30 at 11:40 PM
Veru (VERU) Given a $5.00 Price Target by HC Wainwright AnalystsVeru (VERU) Given a $5.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - March 30 at 1:04 PM
Form 3 VERU INC. For: Mar 20 Filed by: Getzenberg RobertForm 3 VERU INC. For: Mar 20 Filed by: Getzenberg Robert
www.streetinsider.com - March 28 at 8:00 AM
Form 3 VERU INC. For: Mar 20 Filed by: Rankowitz Michael LForm 3 VERU INC. For: Mar 20 Filed by: Rankowitz Michael L
www.streetinsider.com - March 24 at 5:33 PM
Form 4 VERU INC. For: Mar 20 Filed by: Rankowitz Michael L - StreetInsider.comForm 4 VERU INC. For: Mar 20 Filed by: Rankowitz Michael L - StreetInsider.com
www.streetinsider.com - March 23 at 8:10 AM
Form 3 VERU INC. For: Mar 20 Filed by: Rankowitz Michael L - StreetInsider.comForm 3 VERU INC. For: Mar 20 Filed by: Rankowitz Michael L - StreetInsider.com
www.streetinsider.com - March 23 at 8:10 AM
Veru, Inc. (VERU) Says FDA Granted Fee Waiver for Tamsulosin ... - StreetInsider.comVeru, Inc. (VERU) Says FDA Granted Fee Waiver for Tamsulosin ... - StreetInsider.com
www.streetinsider.com - March 23 at 8:10 AM
Veru, Inc. (VERU) Says FDA Granted Fee Waiver for Tamsulosin DRS New Drug ApplicationVeru, Inc. (VERU) Says FDA Granted Fee Waiver for Tamsulosin DRS New Drug Application
www.streetinsider.com - March 22 at 5:45 PM
FDA Grants Fee Waiver for Tamsulosin DRS New Drug ApplicationFDA Grants Fee Waiver for Tamsulosin DRS New Drug Application
finance.yahoo.com - March 22 at 5:45 PM
ZEAL Displays Vigor, MDWD Getting Healed, VERU Up 80% YTD - NasdaqZEAL Displays Vigor, MDWD Getting Healed, VERU Up 80% YTD - Nasdaq
www.nasdaq.com - March 21 at 8:00 AM
Veru, Inc. (VERU) Announces VERU-111 Effective Against Prostate Cancer in Preclinical Study - StreetInsider.comVeru, Inc. (VERU) Announces VERU-111 Effective Against Prostate Cancer in Preclinical Study - StreetInsider.com
www.streetinsider.com - March 17 at 5:40 PM
Pre-Open Movers 03/16: (SEED) (DXR) (VERU) Higher; (OSTK) (TIF) (W) Lower (more...) - StreetInsider.comPre-Open Movers 03/16: (SEED) (DXR) (VERU) Higher; (OSTK) (TIF) (W) Lower (more...) - StreetInsider.com
www.streetinsider.com - March 17 at 5:40 PM

SEC Filings

Veru (NASDAQ:VERU) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Veru (NASDAQ:VERU) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Veru (NASDAQ VERU) Stock Chart for Sunday, June, 17, 2018

Loading chart…

This page was last updated on 6/17/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.